Genomic characterization of clear cell renal cell carcinoma using targeted gene sequencing
Kidney cancer is one of the most lethal cancer types worldwide. The most common subtype of kidney cancer is clear cell renal cell carcinoma (ccRCC), and the somatic mutations of ccRCC have been identified through the development of large databases. The present study aimed to validate the status of t...
Gespeichert in:
Veröffentlicht in: | Oncology letters 2021-02, Vol.21 (2), p.169-169, Article 169 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 169 |
---|---|
container_issue | 2 |
container_start_page | 169 |
container_title | Oncology letters |
container_volume | 21 |
creator | Lin, Po-Hung Huang, Chao-Yuan Yu, Kai-Jie Kan, Hung-Cheng Liu, Chung-Yi Chuang, Cheng-Keng Lu, Yu-Chuan Chang, Ying-Hsu Shao, I-Hung Pang, See-Tong |
description | Kidney cancer is one of the most lethal cancer types worldwide. The most common subtype of kidney cancer is clear cell renal cell carcinoma (ccRCC), and the somatic mutations of ccRCC have been identified through the development of large databases. The present study aimed to validate the status of the associated gene mutations in a Taiwanese cohort. Targeted sequencing was used to validate the mutation status of genes related to ccRCC in Taiwanese patients who had nephrectomy for kidney cancer. The top eight mutated genes in the Catalogue Of Somatic Mutations In Cancer (COSMIC) were selected. These genes were
, protein polybromo-1 (
), histone-lysine N-methyltransferase
, BRCA1-associated protein-1 (
), lysine-specific demethylase 5C (
),
and
. The association between the gene mutation status of
and
was validated with clinicopathological parameters as well as overall survival time. Tumor cells from 96 patients with ccRCC were target sequenced. The order of mutation rate of the eight aforementioned genes was similar to that reported within COSMIC. The present Taiwanese cohort exhibited lower
and
mutation rates compared with average, with increased mutation rates for
and
.
mutation was associated with the tumor and cancerous stage. None of these four genes were positively associated with the overall survival of patients. The
and
mutations were mutually exclusive to
mutation. Overall, the present study provided data confirming gene alteration in Taiwanese patients with ccRCC and showed some differences when compared with Western countries. Further comprehensive genomic and epigenomic studies, as well as downstream validation, are necessary to evaluate the impact of these differences. |
doi_str_mv | 10.3892/ol.2021.12430 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7802514</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A651395123</galeid><sourcerecordid>A651395123</sourcerecordid><originalsourceid>FETCH-LOGICAL-c513t-58559a1f3a1537ac79681a1fb4cdca4ceecb92f81bd23d1058600998c9a3a1823</originalsourceid><addsrcrecordid>eNptkk1v1DAQhiMEolXbI1dkCQlxydYfcWJfkKoKClIlLvTCxZp1JllXXrvYCRL8ehx2u3QR9sFj-5mxZ-atqleMroTS_DL6FaecrRhvBH1WnbJO85pRxZ8f7K45qS5yvqdlyJYp1b6sToRoZCsbeVp9u8EQt84Su4EEdsLkfsHkYiBxINYjJGLRe5IwgN-ZFpJ1xQnInF0YyQRpxAl7MmJAkvH7jKEA43n1YgCf8WK_nlV3Hz98vf5U3365-Xx9dVtbycRUSyWlBjYIYFJ0YDvdKlb268b2FhqLaNeaD4qtey56RqVqKdVaWQ3FRXFxVr3fxX2Y11vsLYYpgTcPyW0h_TQRnDm-CW5jxvjDdIpyyZoS4N0-QIrl83kyW5eXVCFgnLPhTae6TtOGFfTNP-h9nFMpzZ4qde34X2oEj8aFIZZ37RLUXLUlaS0ZF4Va_Ycqs8fSkBhwcOX8yOHtE4cNgp82Ofp5aVc-BusdaFPMOeFwKAajZhGOid4swjF_hFP4108reKAfZSJ-A3pwvHU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2478734572</pqid></control><display><type>article</type><title>Genomic characterization of clear cell renal cell carcinoma using targeted gene sequencing</title><source>Spandidos Publications Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Lin, Po-Hung ; Huang, Chao-Yuan ; Yu, Kai-Jie ; Kan, Hung-Cheng ; Liu, Chung-Yi ; Chuang, Cheng-Keng ; Lu, Yu-Chuan ; Chang, Ying-Hsu ; Shao, I-Hung ; Pang, See-Tong</creator><creatorcontrib>Lin, Po-Hung ; Huang, Chao-Yuan ; Yu, Kai-Jie ; Kan, Hung-Cheng ; Liu, Chung-Yi ; Chuang, Cheng-Keng ; Lu, Yu-Chuan ; Chang, Ying-Hsu ; Shao, I-Hung ; Pang, See-Tong</creatorcontrib><description>Kidney cancer is one of the most lethal cancer types worldwide. The most common subtype of kidney cancer is clear cell renal cell carcinoma (ccRCC), and the somatic mutations of ccRCC have been identified through the development of large databases. The present study aimed to validate the status of the associated gene mutations in a Taiwanese cohort. Targeted sequencing was used to validate the mutation status of genes related to ccRCC in Taiwanese patients who had nephrectomy for kidney cancer. The top eight mutated genes in the Catalogue Of Somatic Mutations In Cancer (COSMIC) were selected. These genes were
, protein polybromo-1 (
), histone-lysine N-methyltransferase
, BRCA1-associated protein-1 (
), lysine-specific demethylase 5C (
),
and
. The association between the gene mutation status of
and
was validated with clinicopathological parameters as well as overall survival time. Tumor cells from 96 patients with ccRCC were target sequenced. The order of mutation rate of the eight aforementioned genes was similar to that reported within COSMIC. The present Taiwanese cohort exhibited lower
and
mutation rates compared with average, with increased mutation rates for
and
.
mutation was associated with the tumor and cancerous stage. None of these four genes were positively associated with the overall survival of patients. The
and
mutations were mutually exclusive to
mutation. Overall, the present study provided data confirming gene alteration in Taiwanese patients with ccRCC and showed some differences when compared with Western countries. Further comprehensive genomic and epigenomic studies, as well as downstream validation, are necessary to evaluate the impact of these differences.</description><identifier>ISSN: 1792-1074</identifier><identifier>EISSN: 1792-1082</identifier><identifier>DOI: 10.3892/ol.2021.12430</identifier><identifier>PMID: 33456545</identifier><language>eng</language><publisher>Greece: Spandidos Publications</publisher><subject>Angiogenesis ; Cancer ; Carcinoma, Renal cell ; Deoxyribonucleic acid ; DNA ; Epigenetics ; Gene mutations ; Genes ; Genetic aspects ; Growth factors ; Hypoxia ; Kidney cancer ; Kinases ; Lysine ; Metastasis ; Methyltransferases ; Mutation ; Oncology ; Pathology ; Proteins ; Tumor proteins</subject><ispartof>Oncology letters, 2021-02, Vol.21 (2), p.169-169, Article 169</ispartof><rights>Copyright: © Lin et al.</rights><rights>COPYRIGHT 2021 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2021</rights><rights>Copyright: © Lin et al. 2021</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c513t-58559a1f3a1537ac79681a1fb4cdca4ceecb92f81bd23d1058600998c9a3a1823</citedby><orcidid>0000-0001-8245-4302</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802514/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802514/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33456545$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lin, Po-Hung</creatorcontrib><creatorcontrib>Huang, Chao-Yuan</creatorcontrib><creatorcontrib>Yu, Kai-Jie</creatorcontrib><creatorcontrib>Kan, Hung-Cheng</creatorcontrib><creatorcontrib>Liu, Chung-Yi</creatorcontrib><creatorcontrib>Chuang, Cheng-Keng</creatorcontrib><creatorcontrib>Lu, Yu-Chuan</creatorcontrib><creatorcontrib>Chang, Ying-Hsu</creatorcontrib><creatorcontrib>Shao, I-Hung</creatorcontrib><creatorcontrib>Pang, See-Tong</creatorcontrib><title>Genomic characterization of clear cell renal cell carcinoma using targeted gene sequencing</title><title>Oncology letters</title><addtitle>Oncol Lett</addtitle><description>Kidney cancer is one of the most lethal cancer types worldwide. The most common subtype of kidney cancer is clear cell renal cell carcinoma (ccRCC), and the somatic mutations of ccRCC have been identified through the development of large databases. The present study aimed to validate the status of the associated gene mutations in a Taiwanese cohort. Targeted sequencing was used to validate the mutation status of genes related to ccRCC in Taiwanese patients who had nephrectomy for kidney cancer. The top eight mutated genes in the Catalogue Of Somatic Mutations In Cancer (COSMIC) were selected. These genes were
, protein polybromo-1 (
), histone-lysine N-methyltransferase
, BRCA1-associated protein-1 (
), lysine-specific demethylase 5C (
),
and
. The association between the gene mutation status of
and
was validated with clinicopathological parameters as well as overall survival time. Tumor cells from 96 patients with ccRCC were target sequenced. The order of mutation rate of the eight aforementioned genes was similar to that reported within COSMIC. The present Taiwanese cohort exhibited lower
and
mutation rates compared with average, with increased mutation rates for
and
.
mutation was associated with the tumor and cancerous stage. None of these four genes were positively associated with the overall survival of patients. The
and
mutations were mutually exclusive to
mutation. Overall, the present study provided data confirming gene alteration in Taiwanese patients with ccRCC and showed some differences when compared with Western countries. Further comprehensive genomic and epigenomic studies, as well as downstream validation, are necessary to evaluate the impact of these differences.</description><subject>Angiogenesis</subject><subject>Cancer</subject><subject>Carcinoma, Renal cell</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>Epigenetics</subject><subject>Gene mutations</subject><subject>Genes</subject><subject>Genetic aspects</subject><subject>Growth factors</subject><subject>Hypoxia</subject><subject>Kidney cancer</subject><subject>Kinases</subject><subject>Lysine</subject><subject>Metastasis</subject><subject>Methyltransferases</subject><subject>Mutation</subject><subject>Oncology</subject><subject>Pathology</subject><subject>Proteins</subject><subject>Tumor proteins</subject><issn>1792-1074</issn><issn>1792-1082</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptkk1v1DAQhiMEolXbI1dkCQlxydYfcWJfkKoKClIlLvTCxZp1JllXXrvYCRL8ehx2u3QR9sFj-5mxZ-atqleMroTS_DL6FaecrRhvBH1WnbJO85pRxZ8f7K45qS5yvqdlyJYp1b6sToRoZCsbeVp9u8EQt84Su4EEdsLkfsHkYiBxINYjJGLRe5IwgN-ZFpJ1xQnInF0YyQRpxAl7MmJAkvH7jKEA43n1YgCf8WK_nlV3Hz98vf5U3365-Xx9dVtbycRUSyWlBjYIYFJ0YDvdKlb268b2FhqLaNeaD4qtey56RqVqKdVaWQ3FRXFxVr3fxX2Y11vsLYYpgTcPyW0h_TQRnDm-CW5jxvjDdIpyyZoS4N0-QIrl83kyW5eXVCFgnLPhTae6TtOGFfTNP-h9nFMpzZ4qde34X2oEj8aFIZZ37RLUXLUlaS0ZF4Va_Ycqs8fSkBhwcOX8yOHtE4cNgp82Ofp5aVc-BusdaFPMOeFwKAajZhGOid4swjF_hFP4108reKAfZSJ-A3pwvHU</recordid><startdate>20210201</startdate><enddate>20210201</enddate><creator>Lin, Po-Hung</creator><creator>Huang, Chao-Yuan</creator><creator>Yu, Kai-Jie</creator><creator>Kan, Hung-Cheng</creator><creator>Liu, Chung-Yi</creator><creator>Chuang, Cheng-Keng</creator><creator>Lu, Yu-Chuan</creator><creator>Chang, Ying-Hsu</creator><creator>Shao, I-Hung</creator><creator>Pang, See-Tong</creator><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8245-4302</orcidid></search><sort><creationdate>20210201</creationdate><title>Genomic characterization of clear cell renal cell carcinoma using targeted gene sequencing</title><author>Lin, Po-Hung ; Huang, Chao-Yuan ; Yu, Kai-Jie ; Kan, Hung-Cheng ; Liu, Chung-Yi ; Chuang, Cheng-Keng ; Lu, Yu-Chuan ; Chang, Ying-Hsu ; Shao, I-Hung ; Pang, See-Tong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c513t-58559a1f3a1537ac79681a1fb4cdca4ceecb92f81bd23d1058600998c9a3a1823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Angiogenesis</topic><topic>Cancer</topic><topic>Carcinoma, Renal cell</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>Epigenetics</topic><topic>Gene mutations</topic><topic>Genes</topic><topic>Genetic aspects</topic><topic>Growth factors</topic><topic>Hypoxia</topic><topic>Kidney cancer</topic><topic>Kinases</topic><topic>Lysine</topic><topic>Metastasis</topic><topic>Methyltransferases</topic><topic>Mutation</topic><topic>Oncology</topic><topic>Pathology</topic><topic>Proteins</topic><topic>Tumor proteins</topic><toplevel>online_resources</toplevel><creatorcontrib>Lin, Po-Hung</creatorcontrib><creatorcontrib>Huang, Chao-Yuan</creatorcontrib><creatorcontrib>Yu, Kai-Jie</creatorcontrib><creatorcontrib>Kan, Hung-Cheng</creatorcontrib><creatorcontrib>Liu, Chung-Yi</creatorcontrib><creatorcontrib>Chuang, Cheng-Keng</creatorcontrib><creatorcontrib>Lu, Yu-Chuan</creatorcontrib><creatorcontrib>Chang, Ying-Hsu</creatorcontrib><creatorcontrib>Shao, I-Hung</creatorcontrib><creatorcontrib>Pang, See-Tong</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncology letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lin, Po-Hung</au><au>Huang, Chao-Yuan</au><au>Yu, Kai-Jie</au><au>Kan, Hung-Cheng</au><au>Liu, Chung-Yi</au><au>Chuang, Cheng-Keng</au><au>Lu, Yu-Chuan</au><au>Chang, Ying-Hsu</au><au>Shao, I-Hung</au><au>Pang, See-Tong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Genomic characterization of clear cell renal cell carcinoma using targeted gene sequencing</atitle><jtitle>Oncology letters</jtitle><addtitle>Oncol Lett</addtitle><date>2021-02-01</date><risdate>2021</risdate><volume>21</volume><issue>2</issue><spage>169</spage><epage>169</epage><pages>169-169</pages><artnum>169</artnum><issn>1792-1074</issn><eissn>1792-1082</eissn><abstract>Kidney cancer is one of the most lethal cancer types worldwide. The most common subtype of kidney cancer is clear cell renal cell carcinoma (ccRCC), and the somatic mutations of ccRCC have been identified through the development of large databases. The present study aimed to validate the status of the associated gene mutations in a Taiwanese cohort. Targeted sequencing was used to validate the mutation status of genes related to ccRCC in Taiwanese patients who had nephrectomy for kidney cancer. The top eight mutated genes in the Catalogue Of Somatic Mutations In Cancer (COSMIC) were selected. These genes were
, protein polybromo-1 (
), histone-lysine N-methyltransferase
, BRCA1-associated protein-1 (
), lysine-specific demethylase 5C (
),
and
. The association between the gene mutation status of
and
was validated with clinicopathological parameters as well as overall survival time. Tumor cells from 96 patients with ccRCC were target sequenced. The order of mutation rate of the eight aforementioned genes was similar to that reported within COSMIC. The present Taiwanese cohort exhibited lower
and
mutation rates compared with average, with increased mutation rates for
and
.
mutation was associated with the tumor and cancerous stage. None of these four genes were positively associated with the overall survival of patients. The
and
mutations were mutually exclusive to
mutation. Overall, the present study provided data confirming gene alteration in Taiwanese patients with ccRCC and showed some differences when compared with Western countries. Further comprehensive genomic and epigenomic studies, as well as downstream validation, are necessary to evaluate the impact of these differences.</abstract><cop>Greece</cop><pub>Spandidos Publications</pub><pmid>33456545</pmid><doi>10.3892/ol.2021.12430</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-8245-4302</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1792-1074 |
ispartof | Oncology letters, 2021-02, Vol.21 (2), p.169-169, Article 169 |
issn | 1792-1074 1792-1082 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7802514 |
source | Spandidos Publications Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Angiogenesis Cancer Carcinoma, Renal cell Deoxyribonucleic acid DNA Epigenetics Gene mutations Genes Genetic aspects Growth factors Hypoxia Kidney cancer Kinases Lysine Metastasis Methyltransferases Mutation Oncology Pathology Proteins Tumor proteins |
title | Genomic characterization of clear cell renal cell carcinoma using targeted gene sequencing |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T18%3A26%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Genomic%20characterization%20of%20clear%20cell%20renal%20cell%20carcinoma%20using%20targeted%20gene%20sequencing&rft.jtitle=Oncology%20letters&rft.au=Lin,%20Po-Hung&rft.date=2021-02-01&rft.volume=21&rft.issue=2&rft.spage=169&rft.epage=169&rft.pages=169-169&rft.artnum=169&rft.issn=1792-1074&rft.eissn=1792-1082&rft_id=info:doi/10.3892/ol.2021.12430&rft_dat=%3Cgale_pubme%3EA651395123%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2478734572&rft_id=info:pmid/33456545&rft_galeid=A651395123&rfr_iscdi=true |